Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908814 | Leukemia Research | 2014 | 7 Pages |
Abstract
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Regina GarcÃa-Delgado, Dunia de Miguel, Alicia Bailén, José Ramón González, Joan Bargay, José F. Falantes, Rafael Andreu, Fernando Ramos, Mar Tormo, Salut Brunet, Antonio Figueredo, Javier Casaño, Ángeles Medina, Llorenç Badiella,